Val
—
Gro
—
Qua
—
Mom
—
Sta
—
Cap—
P/S6.54
P/E—
Fwd P/E21.33
PEG4.26
52W— – —
RSI—
Target$277.91 (+4.6%)
Beta0.23
Div1.97%
Loading chart…
RSI ()
Loading patterns…
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.
Signal
Trend Strength
Price Levels
52-Week Range
52W Low
—
52W High
Position in Range
—
RSI (14)
0 · Oversold
RSI 48
Overbought · 100
Signal
Neutral
EMA Price Levels
Activity & Patterns
Volume Analysis
Momentum Dashboard
Detected Patterns
9Bullish
5Bearish
0Neutral
Key Signals 1
▲ Double Bottom
Major reversal
2026-06-25 · $241.6
Two lows ~$224.17 — bullish reversal confirmed
Learn more →
Momentum Signals 13
▲ MACD Bullish Crossover
▲ MACD Bullish Crossover
▲ MACD Bullish Crossover
▲ Bull Flag
View overlays on the price chart via Overview tab → Pattern Overlays.
EPS — History & Forecast
Estimate
Beat
Miss
Forecast
Loading…
Revenue — History & Forecast
Revenue
Forecast
Loading…
EPS Beat Rate
100%
8/8 quarters
Wall Street Consensus
BUY
BuyHoldSell
Price Target Range
$277.91
+4.6% upside
Low $190
—
High $320
Consensus
Current price
Wall Street Analyst Ratings
Sort by
| Firm | Rating | Change | Action | Date |
|---|
Profitability
Gross Margin
68.14%Last 12 Months
Operating Margin
29.19%Last 12 Months
Return on Equity
25.74%Last 12 Months
Revenue Growth
6.60%Year over Year
Free Cash Flow
16.89BLast 12 Months
Free Cash Flow Yield
—Last 12 Months
Balance Sheet
Debt / Equity
57.71Most Recent Quarter
Current Ratio
1.09Most Recent Quarter
Cash
20.76BMost Recent Quarter
Total Debt
49.04BMost Recent Quarter
Net Debt
—Most Recent Quarter
How JNJ Makes Its Money
Cash Flow Breakdown
Quarterly Metrics
| Quarter | Revenue | Rev YoY | Gross Profit | Op. Income | Net Income | Net YoY | Gross % | Op % | Net % |
|---|
Full Key Statistics
Valuation
| Market Cap | 640.02B |
| Enterprise Value | 668.30B |
| Trailing P/E | 30.88 |
| Forward P/E | 21.33 |
| PEG Ratio (5yr) | 4.26 |
| Price/Sales (ttm) | 6.54 |
| Price/Book (mrq) | 7.53 |
| EV/Revenue | 6.82 |
| EV/EBITDA | 19.16 |
Share Statistics
| Avg Vol (3m) | 7.74M |
| Shares Outstanding | 2.41B |
| Float | 2.41B |
| % Held by Insiders | 0.05% |
| % Held by Institutions | 76.73% |
| Short Ratio | 3.32 |
| Short % of Float | 1.00% |
Profitability
| Gross Margin | 68.14% |
| Operating Margin (ttm) | 29.19% |
| Profit Margin | 21.48% |
| Return on Assets (ttm) | 8.60% |
| Return on Equity (ttm) | 25.74% |
Income Statement
| Revenue (ttm) | 97.93B |
| Revenue Growth (yoy) | 6.60% |
| Gross Profit (ttm) | 66.73B |
| EBITDA | 34.87B |
| Net Income (ttm) | 21.04B |
| Diluted EPS (ttm) | 8.60 |
| EPS Growth (yoy) | -0.90% |
Balance Sheet
| Total Cash (mrq) | 20.76B |
| Total Debt (mrq) | 49.04B |
| Debt / Equity (mrq) | 57.71 |
| Current Ratio (mrq) | 1.09 |
| Book Value / Share | 35.28 |
| Operating CF (ttm) | 27.61B |
| Free Cash Flow (ttm) | 16.89B |
Trading & Dividends
| Beta (5Y) | 0.23 |
| 50-Day MA | 262.48 |
| 200-Day MA | 236.81 |
| Fwd Dividend Yield | 2.01% |
| Payout Ratio | 60.79% |
Income
Dividend Yield
1.97%Last 12 Months
Annual Rate
5.36Forward
Payout Ratio
60.79%Last 12 Months
Dividend History
Payout Ratio (Last 12 Months): 60.79%
Monthly Dividends
Ownership Breakdown
Institutional 76.73%
Insider 0.05%
Public 23.2%
Short Interest
1.00% of float
Low
Institutional 13F Holdings
Famous investors who disclosed a position in JNJ in their latest SEC 13F filing.
Loading…
Insider Transactions
| Date | Insider | Role | Transaction | Shares | Price | Value |
|---|